Centrexion Therapeutics Corp competitors & alternatives

Life Sciences & Healthcare

Semnur Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, non-opioid products for pain management.

Bexson BiomedicalBiotechnologyUnited States

72% match

Similar biotechnology company

Bexson Biomedical is a US-based biopharmaceutical company situated in Santa Barbara, California, focused on the research and development of non-opioid therapeutics and drug delivery systems.

Nocion Therapeutics, Inc.BiotechnologyUnited States

71% matchPrivate

Similar biotechnology company

Nocion Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Watertown, Massachusetts, focused on developing novel therapeutics to treat chronic cough and other conditions.

Daya CNS, LLCBiotechnologyUnited States

70% matchPrivate

Similar biotechnology company

Daya CNS, LLC is a preclinical biopharmaceutical company that develops a proprietary non-opioid pyridoindole platform for the treatment of chronic pain, substance abuse disorders, and neuropsychiatric conditions. Its product pipeline includes small molecule medications such as DDD-028 for neuropathic and inflammatory pain, DDD-024 for addiction, and DDD-016 for neuropsychiatric disorders, serving patients with unmet medical needs in neurology and addiction medicine.

Latigo BiotherapeuticsLTGO · BiotechThousand Oak, United States

70% matchPublic

Biotech

Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its products include Molecule: LTG-001, Molecule: LTG-32, Molecule: LTG-001 IV and Molecule: LTG-418. The company was founded on November 20, 2018 and is headquartered in Thousand Oak, CA.

Exxel Pharma, INC.BiotechnologyUnited States

69% match

Similar biotechnology company

Exxel Pharma is a biopharmaceutical company developing small molecule therapeutics to treat neuronal hypersensitivity disorders, such as refractory chronic cough, neuropathic pain, migraine, and hyperactive bladder. The company utilizes a differentiated approach by selectively inhibiting FAAH peripherally to target first-order sensory neurons while avoiding central nervous system side effects.

Biotech

Cara Therapeutics, Inc. is an emerging biopharmaceutical company with an initial commercial presence, dedicated to the development and commercialization of novel pharmaceutical compounds. Its core mission revolves around addressing pruritus (itching) and pain, primarily by selectively modulating kappa opioid receptors, with a particular focus on the United States. The company's therapeutic pipeline features agents designed to interact with the body's peripheral nervous system and immune cells. Its flagship therapy, KORSUVA (difelikefalin) injection, is approved for managing moderate-to-severe pruritus in adult hemodialysis patients suffering from chronic kidney disease (CKD). Beyond this, Cara Therapeutics is advancing Oral KORSUVA (difelikefalin), which has successfully completed Phase II clinical trials for pruritus associated with atopic dermatitis and non-dialysis-dependent chronic kidney disease (NDD-CKD). This oral formulation is also currently undergoing Phase II trials for pruritus linked to chronic liver disease (CLD), specifically primary biliary cholangitis (PBC), and for notalgia paresthetica. Globally, the company has established strategic license agreements: with Maruishi Pharmaceutical Co., Ltd. for the development, manufacturing, and commercialization of difelikefalin-containing drug products for acute pain and uremic pruritus in Japan; and with Chong Kun Dang Pharmaceutical Corporation for similar activities regarding difelikefalin products in South Korea. Cara Therapeutics, Inc. was established in 2004 and is headquartered in Stamford, Connecticut.

Amalgent Therapeutics, LLCBiotechnologyUnited States

68% matchPrivate

Similar biotechnology company

Amalgent Therapeutics develops fixed-dose combination therapies that pair opioids with dopamine-modulating adjuvants to provide safe pain management. The company's lead program, AMGT-0220, is designed to reduce required opioid doses, mitigate tolerance development, and lower reward signaling to help patients recover without the risks of conventional opioid treatments.

CuraSen Therapeutics, Inc.BiotechnologyUnited States

67% matchPrivate

Similar biotechnology company

CuraSen Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel therapies to treat neurodegenerative diseases by targeting specific receptor systems in the brain. The company's scientific approach focuses on restoring neurovascular and neuronal function to serve patients suffering from conditions such as Parkinson's disease and other neurodegenerative disorders.

Vivamed, Inc.BiotechnologyUnited States

67% match

Similar biotechnology company

VivaMed BioPharma is a clinical-stage biopharmaceutical company that develops new chemical entities and repurposed drugs. It serves the healthcare and research sectors by advancing therapies across neurology, pain, psychiatry, pulmonology, and rheumatology through global partnerships and operator-led development.

Angitia BiopharmaceuticalsBiotechUnited States

67% match

Biotech

Angitia Biopharmaceuticals is a clinical-stage biotechnology company focused on discovering and developing innovative therapeutics for serious musculoskeletal diseases.

Vector Science and Therapeutics Corp.PAIN · BiotechCanada

67% matchPublic

Biotech

Vector Science and Therapeutics Corp. is a medical technology and therapeutic delivery company that develops and sells biomechanical devices and active localized drug delivery platforms. Headquartered in Mequon, Wisconsin, the company focuses on providing clinicians with non-systemic, site-directed technologies. It is publicly listed on the TSXV under the ticker PAIN.V.